Selecta is working on two antigen-specific SVP™ platform applications covering immune tolerance and immune stimulation vaccines.
Selecta’s proprietary Synthetic Vaccine Particle (SVP) technology is designed to encapsulate an immunomodulator in biodegradable particles to selectively modulate an immune response in an antigen‑specific manner:
- induce a tolerogenic response to a biologic drug to mitigate the formation of anti-drug antibodies (ADAs);
- treat a specific allergy or autoimmune disease;
- induce an antigen‑specific stimulatory response, such as an antibody response to a microbial antigen or a cytolytic T cell response to a tumor antigen.